Comparative Pharmacology
Head-to-head clinical analysis: MICORT HC versus POHERDY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICORT HC versus POHERDY.
MICORT-HC vs POHERDY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release, thereby exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
POHERDY is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), binding to domain IV of the extracellular segment, thereby inhibiting ligand-independent HER2 signaling and mediating antibody-dependent cellular cytotoxicity (ADCC).
Topical: Apply a thin film to affected area 2-4 times daily. Rectal: Insert one suppository (25 mg) rectally twice daily (morning and evening) for 2-3 weeks, then taper as needed.
POHERDY: No approved drug. No dosing available.
None Documented
None Documented
Terminal elimination half-life is 1.5-2.5 hours; clinical duration of action is longer due to genomic effects lasting 8-12 hours.
Terminal half-life 12–18 hours (mean 15 h); requires dose adjustment in renal impairment (CrCl <30 mL/min)
Renal (approximately 70% as inactive metabolites, <5% unchanged); fecal (approximately 30%)
Renal: 60% unchanged; fecal/biliary: 30%; 10% metabolized
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid